Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Kalaris Therapeutics (KLRS) EBITDA (2019 - 2020)

Kalaris Therapeutics (KLRS) has 2 years of EBITDA data on record, last reported at -$25.3 million in Q4 2020.

  • For Q4 2020, EBITDA fell 187.91% year-over-year to -$25.3 million; the TTM value through Dec 2020 reached -$70.0 million, changed N/A, while the annual FY2024 figure was -$58.8 million, 69.03% up from the prior year.
  • EBITDA reached -$25.3 million in Q4 2020 per KLRS's latest filing, down from -$23.8 million in the prior quarter.
  • Across five years, EBITDA topped out at -$7.3 million in Q3 2019 and bottomed at -$25.3 million in Q4 2020.